<p>Biodesix, Inc.（纳斯达克代码：BDSX - 获取免费报告）的股票在目前覆盖该股票的六家评级公司中获得了 “适度买入” 的平均推荐，Marketbeat.com 报道。一位分析师给予该股票卖出评级，一位给予持有评级，四位则对该公司给予买入评级。在过去一年中，给予该股票评级的分析师的平均十二个月目标价为 32.50 美元。</p>
<p>多家券商最近对 BDSX 发布了报告。华尔街禅在 11 月 8 日（星期六）的一份研究报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了对 Biodesix 股票的 “卖出（e+）” 评级。最后，Canaccord Genuity Group 在 9 月 19 日（星期五）的一份研究报告中设定了 Biodesix 股票的 20.00 美元目标价，并给予该公司 “买入” 评级。</p>
<p><strong>获取我们对 Biodesix 的最新股票分析</strong></p>
<h2>Biodesix 股票表现</h2>
<p>Biodesix 股票在星期四开盘价为 7.87 美元。Biodesix 的 12 个月低点为 3.44 美元，12 个月高点为 32.20 美元。该公司的流动比率为 1.84，速动比率为 1.84，债务与股本比率为 41.11。该公司的 50 日简单移动平均线为 7.34 美元，200 日简单移动平均线为 7.14 美元。该公司的市值为 6265 万美元，市盈率为-1.42，贝塔值为 0.98。</p>
<p>Biodesix（纳斯达克代码：BDSX - 获取免费报告）在 11 月 3 日（星期一）最后发布了其财报。该公司报告本季度每股收益（EPS）为（1.16 美元），超出分析师共识预期的（1.60 美元）0.44 美元。该季度的营业收入为 2177 万美元，而共识预期为 2098 万美元。Biodesix 的股本回报率为-504.41%，净利润率为-49.31%。Biodesix 已设定其 2025 财年的指导目标为每股收益。卖方分析师预测 Biodesix 本年度将发布-0.35 的每股收益。</p>
<h2>内部交易活动</h2>
<p>在相关消息中，董事杰克·W·舒勒在 9 月 19 日（星期五）以每股平均价格 7.04 美元购买了 142,045 股公司的股票，总交易额为 999,996.80 美元。交易完成后，该董事直接持有公司 1,380,745 股股票，估值约为 9,720,444.80 美元。此次交易使其持股增加了 11.47%。该交易已在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过此超链接访问。在上个季度，内部人士购买了 334,836 股公司股票，价值 2,611,362 美元，并出售了 300 股，价值 2,286 美元。目前，30.10% 的股票由公司内部人士持有。</p>
<h2>Biodesix 的机构交易</h2>
<p>多家对冲基金和其他机构投资者最近对该股票的持仓进行了调整。Millennium Management LLC 在第三季度购买了 Biodesix 的新股份，价值约为 113,000 美元。Oracle Investment Management Inc. 在第三季度购买了 Biodesix 股票的新股份，价值约为 113,000 美元。XTX Topco Ltd 在第一季度购买了 Biodesix 股票的新股份，价值约为 64,000 美元。Blair William &amp; Co. IL 在第一季度将其在 Biodesix 股票中的持仓增加了 33.3%。Blair William &amp; Co. IL 目前持有 124,100 股公司股票，价值 78,000 美元，此前在该期间内又购买了 31,000 股。最后，Monashee Investment Management LLC 在第一季度将其在 Biodesix 股票中的持仓增加了 15.7%。Monashee Investment Management LLC 目前持有 4,050,000 股公司股票，价值 2,532,000 美元，此前在该期间内又购买了 549,121 股。目前，20.96% 的股票由机构投资者持有。</p>
<h2>Biodesix 公司简介</h2>
<p>（获取免费报告）</p>
<p>Biodesix, Inc. 在美国作为一家数据驱动的诊断解决方案公司运营。该公司提供基于血液的肺部测试，包括 Nodify XL2 和 Nodify CDT 测试，统称为 Nodify 肺结节风险评估测试策略，以评估肺癌风险并帮助识别适当的治疗路径，并帮助医生重新分类可疑肺结节患者的恶性风险。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>10 美元以下的最佳股票</li>
<li>为什么黄金如此热爱特朗普，就像特朗普热爱黄金一样</li>
<li>什么是财报？</li>
<li>谷歌的 Gemini 3 让博通飙升：TPU 成为焦点</li>
<li>3 个股票代码引领了 meme 股票的复兴</li>
<li>Palantir 不仅仅是在乘风 AI 热潮——它正在指挥这一切</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Biodesix 吗？</h2>
<p>在你考虑 Biodesix 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Biodesix 并不在名单上。</p>
<p>虽然 Biodesix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BDSX

<p>Biodesix, Inc.（纳斯达克代码：BDSX）获得了六位分析师的 “适度买入” 推荐，其中一位为卖出，一位为持有，四位为买入评级。平均目标价为 32.50 美元。最近的升级包括华尔街 Zen 将评级从 “卖出” 调整为 “持有”。该股票开盘价为 7.87 美元，12 个月的价格区间为 3.44 美元至 32.20 美元。内部人士 Jack W. Schuler 增加了 11.47% 的持股比例。机构投资者持有该股票的 20.96%</p>

<p>Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have earned an average recommendation of &#34;Moderate Buy&#34; from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $32.50.</p>
<div class="lb-trans"><p>Biodesix, Inc.（纳斯达克代码：BDSX - 获取免费报告）的股票在目前覆盖该股票的六家评级公司中获得了 “适度买入” 的平均推荐，Marketbeat.com 报道。一位分析师给予该股票卖出评级，一位给予持有评级，四位则对该公司给予买入评级。在过去一年中，给予该股票评级的分析师的平均十二个月目标价为 32.50 美元。</p>
</div><p>A number of brokerages recently issued reports on BDSX. Wall Street Zen upgraded Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Biodesix in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group set a $20.00 price target on shares of Biodesix and gave the company a &#34;buy&#34; rating in a research note on Friday, September 19th.</p>
<div class="lb-trans"><p>多家券商最近对 BDSX 发布了报告。华尔街禅在 11 月 8 日（星期六）的一份研究报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了对 Biodesix 股票的 “卖出（e+）” 评级。最后，Canaccord Genuity Group 在 9 月 19 日（星期五）的一份研究报告中设定了 Biodesix 股票的 20.00 美元目标价，并给予该公司 “买入” 评级。</p>
</div><p><strong>Get Our Latest Stock Analysis on Biodesix</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Biodesix 的最新股票分析</strong></p>
</div><h2>Biodesix Price Performance</h2>
<div class="lb-trans"><h2>Biodesix 股票表现</h2>
</div><p>Biodesix stock opened at $7.87 on Thursday. Biodesix has a 12 month low of $3.44 and a 12 month high of $32.20. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The business's 50 day simple moving average is $7.34 and its 200 day simple moving average is $7.14. The company has a market cap of $62.65 million, a price-to-earnings ratio of -1.42 and a beta of 0.98.</p>
<div class="lb-trans"><p>Biodesix 股票在星期四开盘价为 7.87 美元。Biodesix 的 12 个月低点为 3.44 美元，12 个月高点为 32.20 美元。该公司的流动比率为 1.84，速动比率为 1.84，债务与股本比率为 41.11。该公司的 50 日简单移动平均线为 7.34 美元，200 日简单移动平均线为 7.14 美元。该公司的市值为 6265 万美元，市盈率为-1.42，贝塔值为 0.98。</p>
</div><p>Biodesix (NASDAQ:BDSX - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Biodesix has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Biodesix will post -0.35 EPS for the current year.</p>
<div class="lb-trans"><p>Biodesix（纳斯达克代码：BDSX - 获取免费报告）在 11 月 3 日（星期一）最后发布了其财报。该公司报告本季度每股收益（EPS）为（1.16 美元），超出分析师共识预期的（1.60 美元）0.44 美元。该季度的营业收入为 2177 万美元，而共识预期为 2098 万美元。Biodesix 的股本回报率为-504.41%，净利润率为-49.31%。Biodesix 已设定其 2025 财年的指导目标为每股收益。卖方分析师预测 Biodesix 本年度将发布-0.35 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, Director Jack W. Schuler bought 142,045 shares of the company's stock in a transaction on Friday, September 19th. The shares were purchased at an average price of $7.04 per share, for a total transaction of $999,996.80. Following the completion of the transaction, the director directly owned 1,380,745 shares in the company, valued at approximately $9,720,444.80. The trade was a 11.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders acquired 334,836 shares of company stock worth $2,611,362 and sold 300 shares worth $2,286. 30.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事杰克·W·舒勒在 9 月 19 日（星期五）以每股平均价格 7.04 美元购买了 142,045 股公司的股票，总交易额为 999,996.80 美元。交易完成后，该董事直接持有公司 1,380,745 股股票，估值约为 9,720,444.80 美元。此次交易使其持股增加了 11.47%。该交易已在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过此超链接访问。在上个季度，内部人士购买了 334,836 股公司股票，价值 2,611,362 美元，并出售了 300 股，价值 2,286 美元。目前，30.10% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Biodesix</h2>
<div class="lb-trans"><h2>Biodesix 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC purchased a new stake in Biodesix during the 3rd quarter worth about $113,000. Oracle Investment Management Inc. bought a new stake in shares of Biodesix during the third quarter valued at about $113,000. XTX Topco Ltd purchased a new stake in shares of Biodesix in the first quarter worth about $64,000. Blair William &amp; Co. IL boosted its position in shares of Biodesix by 33.3% in the first quarter. Blair William &amp; Co. IL now owns 124,100 shares of the company's stock valued at $78,000 after acquiring an additional 31,000 shares during the period. Finally, Monashee Investment Management LLC boosted its position in shares of Biodesix by 15.7% in the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company's stock valued at $2,532,000 after acquiring an additional 549,121 shares during the period. 20.96% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>多家对冲基金和其他机构投资者最近对该股票的持仓进行了调整。Millennium Management LLC 在第三季度购买了 Biodesix 的新股份，价值约为 113,000 美元。Oracle Investment Management Inc. 在第三季度购买了 Biodesix 股票的新股份，价值约为 113,000 美元。XTX Topco Ltd 在第一季度购买了 Biodesix 股票的新股份，价值约为 64,000 美元。Blair William &amp; Co. IL 在第一季度将其在 Biodesix 股票中的持仓增加了 33.3%。Blair William &amp; Co. IL 目前持有 124,100 股公司股票，价值 78,000 美元，此前在该期间内又购买了 31,000 股。最后，Monashee Investment Management LLC 在第一季度将其在 Biodesix 股票中的持仓增加了 15.7%。Monashee Investment Management LLC 目前持有 4,050,000 股公司股票，价值 2,532,000 美元，此前在该期间内又购买了 549,121 股。目前，20.96% 的股票由机构投资者持有。</p>
</div><h2>Biodesix Company Profile</h2>
<div class="lb-trans"><h2>Biodesix 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.</p>
<div class="lb-trans"><p>Biodesix, Inc. 在美国作为一家数据驱动的诊断解决方案公司运营。该公司提供基于血液的肺部测试，包括 Nodify XL2 和 Nodify CDT 测试，统称为 Nodify 肺结节风险评估测试策略，以评估肺癌风险并帮助识别适当的治疗路径，并帮助医生重新分类可疑肺结节患者的恶性风险。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>Best Stocks Under $10.00</li>
<li>Why Gold Loves Trump as Much as Trump Loves Gold</li>
<li>What Are Earnings Reports?</li>
<li>Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>10 美元以下的最佳股票</li>
<li>为什么黄金如此热爱特朗普，就像特朗普热爱黄金一样</li>
<li>什么是财报？</li>
<li>谷歌的 Gemini 3 让博通飙升：TPU 成为焦点</li>
<li>3 个股票代码引领了 meme 股票的复兴</li>
<li>Palantir 不仅仅是在乘风 AI 热潮——它正在指挥这一切</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BDSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Biodesix 吗？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Biodesix 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Biodesix 并不在名单上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biodesix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Biodesix 公司（NASDAQ:BDSX）被分析师给予 “适度买入” 的平均评级